Farhan Raza Khan

Farhan Raza Khan

Auto-generated profile, based on publicly available information

Farhan Raza Khan

Department of Dentistry and Oral Health Sciences, Aga Khan University Hospital, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Dental Traumatology
Verified
Journal Article
Closed access
PDF file
SASamira Adnan
Samira Adnan
MLMaham Muneeb Lone
Maham Muneeb Lone
FKFarhan Raza Khan
Farhan Raza Khan
SHSyeda Mahvash Hussain
Syeda Mahvash Hussain
SNSana E. Nagi
Sana E. Nagi


14 September 2020 in Trials
Verified
Journal Article
Open access
PDF file
FKFarhan Raza Khan
Farhan Raza Khan
SKSyed Murtaza Raza Kazmi
Syed Murtaza Raza Kazmi
NINajeeha Talat Iqbal
Najeeha Talat Iqbal
JIJunaid Iqbal
Junaid Iqbal
Syed Tariq AliSyed Tariq Ali
Syed Tariq Ali
SASyed Akbar Abbas
Syed Akbar Abbas
Objectives: 1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive patients. 2- To determine the salivary cytokine profiles of IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL- 17 among COVID-19 patients subjected to 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline or Neem extract (Azardirachta indica) based gargles. Trial design: This will be a parallel group, quadruple blind-randomised controlled pilot trial with an add on laboratory based study. Participants: A non-probability, purposive sampling technique will be followed to identify participants for this study. The clinical trial will be carried out at the Aga Khan University Hospital (AKUH), Karachi, Pakistan. The viral PCR tests will be done at main AKUH clinical laboratories whereas the immunological tests (cytokine analysis) will be done at the Juma research laboratory of AKUH. The inclusion criteria are laboratory-confirmed COVID-19 positive patients, male or female, in the age range of 18-65 years, with mild to moderate disease, already admitted to the AKUH. Subjects with low Glasgow coma score, with a history of radiotherapy or chemotherapy, who are more than 7 days past the onset of COVID- 19 symptoms, or intubated or edentulous patients will be excluded. Patients who are being treated with any form of oral or parenteral antiviral therapy will be excluded, as well as patients with known pre-existing chronic mucosal lesions such as lichen planus. Intervention and comparator: Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.) for 20-30 seconds, thrice daily for 6 days. Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.) for 20-30 seconds, thrice daily for 6 days. Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated by Karachi University (chemistry department laboratories) for 20-30 seconds, thrice daily for 6 days. Group D (n=10) patients will use 2% hypertonic saline (Plabottle® by Otsuka Inc.) gargle and nasal lavage for a similar time period. Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days. For nasal lavage, a special douche syringe will be provided to each participant. Its use will be thoroughly explained by the data collection officer. After each use, the patient is asked not to eat, drink, or rinse their mouth for the next 30 minutes. Main outcomes: The primary outcome is the reduction in the intra-oral viral load confirmed with real time quantitative PCR. Randomisation: The assignment to the study group/ allocation will be done using the sealed envelope method under the supervision of Clinical Trial Unit (CTU) of Aga Khan University, Karachi, Pakistan. The patients will be randomised to their respective study group (1:1:1:1:1 allocation ratio) immediately after the eligibility assessment and consent administration is done. Blinding (masking): The study will be quadruple-blinded. Patients, intervention provider, outcome assessor and the data collection officer will be blinded. The groups will be labelled as A, B, C, D or E. The codes of the intervention will be kept in lock & key at the CTU and will only be revealed at the end of study or if the study is terminated prematurely. Numbers to be randomised (sample size): As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. The present study will serve as a pilot trial. We intend to study 50 patients in five study groups with 10 patients in each study group. For details, please refer to Fig. 1 for details. Trial Status: Protocol version is 7.0, approved by the department and institutional ethics committees and clinical trial unit of the university hospital. Recruitment is planned to start as soon as the funding is sanctioned. The total duration of the study is expected to be 6 months i.e. August 2020-January 2021. Trial registration: This study protocol was registered at www.clinicaltrials.gov on 10 April 2020 NCT04341688. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).


1 January 2018 in Journal of the College of Physicians and Surgeons Pakistan
Verified
Journal Article
Closed access
FKFarhan Raza Khan
Farhan Raza Khan
TATashfeen Ahmad
Tashfeen Ahmad
Rabia HussainRabia Hussain
Rabia Hussain
ZBZulfiqar Bhutta
Zulfiqar Bhutta
To determine if low birth weight is associated with hypovitaminosis D and periodontal disease among a sample of Pakistani women residing in district Jhelum, Punjab. Cross-sectional study nested in a large community-based longitudinal study. Tehsil Pind Dadan Khan, District Jhelum, Pakistan from August 2012 to October 2015. Women during 12-16th week of pregnancy were selected. Dental examination was performed. Probing depth >3 mm was labeled as periodontal disease, whereas serum level <20.0 ng/mL was taken as hypovitaminosis D. Mothers of low birth weight babies (2500 g) babies. Odds ratio was applied to measure the strength of association of low birth weight with maternal hypovitaminosis D and also for maternal periodontal disease. There were 62 participants in the study. The mean age of mothers was 26.7 ±4.5 years. It was alarming to observe that 53 (85%) participants had vitamin D deficiency. However, periodontal disease was only seen in four participants (6%). Out of the 62 mothers, eighteen (29%) gave birth to low birth weight babies. None of the variables were found to be associated with the low birth weight. The present study did not find any significant association of low birth weight with hypovitaminosis D or maternal periodontal disease in the studied sample.

30 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WJWafa Jamal
Wafa Jamal
FKFarhan Raza Khan
Farhan Raza Khan
NZNadeem Zuberi
Nadeem Zuberi
SKSyed Murtaza Raza Kazmi
Syed Murtaza Raza Kazmi
SRShafquat Rozi
Shafquat Rozi
Due to the overlapping aetiology of Gestational Diabetes Mellitus (GDM) and Periodontal disease (PD), which are prevalent metabolic disorder and chronic inflammatory disorder in pregnant women respectively, they are often at risk of developing both diseases simultaneously. This study aims to evaluate the association of periodontal disease and gestational diabetes mellitus among post-partum women who delivered within 24 h at private tertiary care hospital, Karachi, Pakistan. Analytical cross sectional study with sample size of 178 by non- probability purposive sampling, a total of 101 postpartum women (57%) were diagnosed with periodontal disease and 50 (28%) were GDM positive. Of those who had PD, 35% (n = 35/101) were GDM positive. An insignificant association of the prevalence ratio of GDM in women with periodontal disease was found. [PR = 1.7; 95% CI: 0.2–3.2; p-value 0.07] A statistically significant association was found between the prevalence ratio of GDM in women with obesity. It was 2.6 times compared to women who were not obese (p value < 0.01, 95% CI: 1.3–5.1). There is insignificant association found between the prevalence ratio of GDM in women with periodontal disease in our setting. Women who are overweight or tend to gain weight should be closely monitored and guided to take dietary measures.